IO Biotech's Cylembio Cancer Vaccine Misses Primary Endpoint in Phase 3 Melanoma Trial
Key Insights
IO Biotech announced that its cancer vaccine Cylembio (search) combined with KEYTRUDA showed improvement in progression-free survival over KEYTRUDA alone but narrowly missed statistical significance for the primary endpoint in advanced melanoma (search).
The disappointing Phase 3 trial results caused IO Biotech's stock to plunge 34.25% to $1.19, with trading volume surging to 70.37 million shares compared to the average of 0.32 million shares.
Despite the setback, analysts maintain an average target price of $8.20, indicating a potential 324% upside, while the company continues development of its T-Win Technology platform for off-the-shelf therapeutic vaccines.
IO Biotech announced disappointing topline results from its pivotal Phase 3 trial of the cancer vaccine Cylembio (search) in combination with Merck (search)'s KEYTRUDA for advanced melanoma (search), causing the company's stock to plummet 34.25% to $1.19 on Monday. While the treatment demonstrated improvement in progression-free survival over KEYTRUDA alone, it narrowly missed statistical significance for the primary endpoint.
Market Response and Trading Activity
The negative trial results triggered a dramatic market reaction, with IO Biotech shares opening at $1.88 and trading between $1.18 and $2.04 throughout the session. Trading volume surged to 70.37 million shares, representing a massive increase from the average daily volume of 0.32 million shares on the Nasdaq. The company's 52-week trading range spans from $0.66 to $2.48.
Clinical Development Pipeline
IO Biotech is developing off-the-shelf therapeutic vaccines using its proprietary T-Win Technology platform. The company's lead candidate, cylembio (search) (IO102-IO103), is being evaluated in the phase 3 IOB-013/KN-D18 trial in combination with KEYTRUDA (pembrolizumab) for treating first-line unresectable or metastatic melanoma patients.
Beyond the melanoma indication, IO Biotech has two ongoing basket studies exploring cylembio (search)'s potential in additional cancer types. One phase 2 study examines cylembio combined with KEYTRUDA in the perioperative setting for resectable squamous cell carcinoma of the head and neck (search) (SCCHN) and melanoma patients. The second phase 2 study evaluates the combination for treating advanced SCCHN and non-small cell lung cancer (search) (NSCLC). Updated data from these studies are expected in the second half of 2025.
Financial Position and Analyst Outlook
Despite the clinical setback, IO Biotech maintains a solid financial foundation with cash and cash equivalents of $37.1 million as of March 31, 2025. The company has established a loan facility with the European Investment Bank (search) (EIB) and has drawn upon the first tranche of $11.72 million. Management believes current cash reserves will fund operations into Q2 2026, though the company burns approximately $22.6 million per quarter, with $16.4 million allocated to R&D expenses and $6.2 million to general and administrative costs.
Remarkably, analysts remain optimistic about IO Biotech's prospects despite the Phase 3 miss. The average analyst target price stands at $8.20, suggesting a potential 324.87% upside from the current trading price of $1.93. The average brokerage recommendation is 2.0, indicating an "Outperform" status.
Share Offering and Strategic Considerations
IO Biotech has filed to offer 4.22 million shares of common stock, allowing existing shareholders to sell their shares in the market. This move could impact the stock's market dynamics as the company navigates the aftermath of its clinical disappointment.
The primary risks facing IO Biotech center on the uncertainty surrounding its clinical programs. There remains no assurance that future trials will achieve statistically significant endpoints, and regulatory approval for cylembio (search) is not guaranteed. The ongoing basket studies also present execution risks, with no certainty that results will be sufficient to advance these programs into phase 3 development.